TRIM28

Across TCGA pan-cancer cohorts, TRIM28 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRIM28 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRIM28 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TRIM28 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

HNSC, GBM, and UCEC are the cancer types where TRIM28 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.601	0.924	<.001	91	view →
GBM	OS	Quartile	All	0.652	0.296	.013	8	view →
UCEC	DFS	Median	II,III,IV	0.534	0.867	.040	4	view →
CCRCC	OS	Median	All	0.911	1.000	.023	3	view →
LUAD	DFS	Median	III,IV	0.973	0.508	.032	3	view →
LSCC	OS	Median	III,IV	0.638	0.986	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRIM28–HNSC (OS)

Open the HNSC breakdown →